BOROSCINSEQ2FY26November 12, 2025

Borosil Scientific Limited

3,152words
5turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs,
November 12, 2025 BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001 The National Stock Exchange of India Limited Exchange Plaza, C-1,
6.5GW
ic Ltd INDIA’s first and largest solar glass manufacturer with a combined capacity of 1000 TPD (~6.5GW) ₹9801*cr Market Cap Note: *As on 11th Nov 2025- NSE One of the Market leaders in Consumer ware
₹9801
INDIA’s first and largest solar glass manufacturer with a combined capacity of 1000 TPD (~6.5GW) ₹9801*cr Market Cap Note: *As on 11th Nov 2025- NSE One of the Market leaders in Consumer ware and Kit
₹4051
ne of the Market leaders in laboratory glassware and Scientific instruments and Process sciences ₹4051*cr Market Cap ₹1142*cr Market Cap 3 Legacy and Leadership Borosil Scientific is considered as t
₹1142
ers in laboratory glassware and Scientific instruments and Process sciences ₹4051*cr Market Cap ₹1142*cr Market Cap 3 Legacy and Leadership Borosil Scientific is considered as the GOLD standard in l
13.8%
Q2FY26 14 Particulars (₹ Crs)Q2FY26Q1FY26Q2FY25YoY%Q2FY26Q1FY26Q2FY25YoY%Net Sales99.5 89.0 87.4 13.8%106.9 96.0 103.0 3.8%EBITDA14.6 11.9 15.2 -4.1%10.2 7.8 17.4 -41.5%EBITDA (%)14.7%13.4%17.4%9.5%8.1%
3.8%
rs (₹ Crs)Q2FY26Q1FY26Q2FY25YoY%Q2FY26Q1FY26Q2FY25YoY%Net Sales99.5 89.0 87.4 13.8%106.9 96.0 103.0 3.8%EBITDA14.6 11.9 15.2 -4.1%10.2 7.8 17.4 -41.5%EBITDA (%)14.7%13.4%17.4%9.5%8.1%16.9%EBIT10.2 7.5 11.
4.1%
25YoY%Q2FY26Q1FY26Q2FY25YoY%Net Sales99.5 89.0 87.4 13.8%106.9 96.0 103.0 3.8%EBITDA14.6 11.9 15.2 -4.1%10.2 7.8 17.4 -41.5%EBITDA (%)14.7%13.4%17.4%9.5%8.1%16.9%EBIT10.2 7.5 11.0 -7.0%5.4 2.9 12.8 -58.0%
41.5%
2FY25YoY%Net Sales99.5 89.0 87.4 13.8%106.9 96.0 103.0 3.8%EBITDA14.6 11.9 15.2 -4.1%10.2 7.8 17.4 -41.5%EBITDA (%)14.7%13.4%17.4%9.5%8.1%16.9%EBIT10.2 7.5 11.0 -7.0%5.4 2.9 12.8 -58.0%PBT10.1 0.7 10.8 -6.
14.7%
les99.5 89.0 87.4 13.8%106.9 96.0 103.0 3.8%EBITDA14.6 11.9 15.2 -4.1%10.2 7.8 17.4 -41.5%EBITDA (%)14.7%13.4%17.4%9.5%8.1%16.9%EBIT10.2 7.5 11.0 -7.0%5.4 2.9 12.8 -58.0%PBT10.1 0.7 10.8 -6.3%5.1 -4.1 12.4
13.4%
.5 89.0 87.4 13.8%106.9 96.0 103.0 3.8%EBITDA14.6 11.9 15.2 -4.1%10.2 7.8 17.4 -41.5%EBITDA (%)14.7%13.4%17.4%9.5%8.1%16.9%EBIT10.2 7.5 11.0 -7.0%5.4 2.9 12.8 -58.0%PBT10.1 0.7 10.8 -6.3%5.1 -4.1 12.4 -58.
17.4%
.0 87.4 13.8%106.9 96.0 103.0 3.8%EBITDA14.6 11.9 15.2 -4.1%10.2 7.8 17.4 -41.5%EBITDA (%)14.7%13.4%17.4%9.5%8.1%16.9%EBIT10.2 7.5 11.0 -7.0%5.4 2.9 12.8 -58.0%PBT10.1 0.7 10.8 -6.3%5.1 -4.1 12.4 -58.6%PAT
Guidance — 4 items
Note
opening
1) Standalone EBITDA in Q2 FY26 & H1FY26 declined primarily due to one-time expenses related to the discontinued operations at the Ambad manufacturing plant (other than VRS), which includes discarding of fixed assets and Consolidated EBITDA in Q2FY26 & H1FY26 declined further due to lower sales in Goel Scientific Glass Works Limited.
Note
opening
1) Process System had a revenue degrowth due to a significantly lower opening order book as of 1 July 2025 that would be available for execution during Q2 FY26.
Note
opening
Some of the key customers’ order got delayed and their execution is deferred to Q3 FY26 due to various reasons and hence the sale in Q2 FY26 got impacted.
Note
opening
Encouragingly, fresh order bookings in H1 FY26 were substantially higher than last year, a considerably large part of these order is due for execution Q3FY26, order booking for H2FY26 looks promising which will positively impact our H2FY26 sales.
Advertisement
Risks & concerns — 1 flagged
2) In Pharma Packaging, the temporary decline in performance during H1FY26 was primarily due to gaps in operational efficiencies at the plant.
Note
Speaking time
Note
2
Sub
1
Gold Standard In Quality
1
Estimated Market Growth
1
Advertisement
Opening remarks
Sub
Investor presentation on the Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2025 Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the presentation on the Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2025. The said presentation is also hosted on the Company's website at Investor Presentation - Borosil Scientific. Please take the above on record. Thanking You, Yours faithfully, For Borosil Scientific Limited Sanjay Gupta Company Secretary & Compliance Officer ICSI Membership No.: A24641 Encl: as above Enabling the Future of Science Investor Presentation Q2FY26 Safe Harbour This investor presentation has been prepared by Borosil Scientific Limited (“Company”) on a strictly confidential basis. Certain statements in this presentation may be ‘fo
Gold Standard In Quality
Products Meet ISO, ASTM, and ISI Certifications. Trusted Worldwide : NABL accredited Calibration Lab; ISO 9001:2015, 14001, 45001, and 15378 Certifications Default Choice 3 Out Of 4 Lab Glassware Products In India Bear The Borosil Name. 4,000+ SKUs Serving Pharmaceuticals, Research, Academia, and Industries Across India 4 A Legacy of more than 6 decades… Current Indian promoters took over Entry in Pharma Primary Packaging with acquisition of Klasspack pvt ltd, Nasik Entry into Process System through acquisition of Goel Scientific Glass Works, Baroda Brand Borosil came into existence Shifted manufacturing base from Mumbai to Bharuch Instituted greenfield manufacturing plant for Laboratory Instruments, Pune Scientific Division demerged from Borosil Ltd on 2nd Dec 2023 and got listed as Borosil Scientific Limited on 7th June 1962 1988 2008 2016 2018 2023 2024 5 Vision To be the most customer-centric company Purpose Being an Indian manufacturer, our purpose is to develop safe and high-qual
Note
1) Standalone EBITDA in Q2 FY26 & H1FY26 declined primarily due to one-time expenses related to the discontinued operations at the Ambad manufacturing plant (other than VRS), which includes discarding of fixed assets and Consolidated EBITDA in Q2FY26 & H1FY26 declined further due to lower sales in Goel Scientific Glass Works Limited. 2) The Company had introduced a Voluntary Retirement Scheme (VRS) for the eligible workers at its Ambad, Nashik plant. In H1FY26, the Company entered into a Memorandum of Settlement with the Bhartiya Kamgar Sena (BKS), the registered trade union representing these workers. The settlement, including related professional fees, resulted in an expense of ₹6.61 crores, which is an exceptional item. 15 Particulars (₹ Crs)H1FY26H1FY25YoY%H1FY26H1FY25YoY%Net Sales188.5 181.1 4.1%202.9 207.5 -2.3%EBITDA26.5 28.3 -6.3%18.0 29.4 -38.8%EBITDA (%)14.1%15.6%8.9%14.2%EBIT17.7 19.9 -11.1%8.3 20.2 -59.0%PBT10.8 19.5 -44.6%1.1 19.4 -94.6%PAT8.0 14.2 -43.7%-1.4 13.8 -109.9%N
Note
1) Process System had a revenue degrowth due to a significantly lower opening order book as of 1 July 2025 that would be available for execution during Q2 FY26. Some of the key customers’ order got delayed and their execution is deferred to Q3 FY26 due to various reasons and hence the sale in Q2 FY26 got impacted. Encouragingly, fresh order bookings in H1 FY26 were substantially higher than last year, a considerably large part of these order is due for execution Q3FY26, order booking for H2FY26 looks promising which will positively impact our H2FY26 sales. 2) In Pharma Packaging, the temporary decline in performance during H1FY26 was primarily due to gaps in operational efficiencies at the plant. We have since addressed this by appointing seasoned industry professionals to lead operations, which has already started improving output. In parallel, order bookings across key product categories have strengthened significantly. This positive momentum is already visible in Q2FY26 performance,
Estimated Market Growth
6% to 8% Estimated Market Growth : 12% to 14% Glassware Segment Pharmaceutical Primary Packaging Serviceable Addressable Market : ₹1377 Cr Estimated Market Growth : 9%to10% Source: F&S 2019 report, Industry & Internal Estimates 20 New Product Development Fat with randall Fiber with fiber bags Moisture analyser Handheld Photometer Vial Inserts Micro Vials UV Visible Spectrophotometer e-dispenser e-Titrate Over head Stirrer Hot plate stirrer Quartz Distillation Unit 21 Emphasis on Environmental Testing Products Chemical Analysis Inorganic | Metal | Heavy Metals Electrochemistry Prime Lab 2.0 COD Digestor pH Meter Cond / TDS Meter Dissolved Oxygen Meter BOD System Comparator Tests Chemistry Kits Turbidity Meter 22 ISI Glassware Certification Achieved within 6 Months NO. 1 IN KJELDAHL Approx 750+ installations in a 5 Years Patented Bottle Top Dispenser DIY CALIBRATION A PATENTED PRODUCT 8000+ in last 3 years Worldwide Product Presence 90+ Countries Laboratory Glassware Pharma Primary Packi
Advertisement
← All transcriptsBOROSCI stock page →